Health
Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025
NANJING, China, Nov. 4, 2025 /PRNewswire/ -- Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the 67th Annual Meeting of the American Society of ...
2025-11-04 09:50
927
ICP DAS-BMP Redefines Medical Material Performance with Low-Migration and Low-Friction TPU at COMPAMED 2025
HSINCHU, Nov. 4, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation inCOMPAMED 2025, taking place fromNovember 17 to 20 at Messe Düsseldorf, Germany. Visitors ...
2025-11-04 08:45
1086
CQ Medical® Appoints Michael Galbus as Chief Executive Officer, Mike Sutter as Chairman of the Board of Directors
AVONDALE, Pa., Nov. 4, 2025 /PRNewswire/ -- CQ Medical is pleased to announce the appointment ofMichael Galbus as Chief Executive Officer. Michael previously served as Chief Operating Officer, where he played a key role in enhancing operational performance, advancing the company's growth strategy...
2025-11-04 02:00
979
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ ...
2025-11-03 22:15
1565
Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agree...
2025-11-03 22:00
1509
EmeTerm Wristband Significantly Reduces Postoperative Nausea and Vomiting in Major Orthopedic Surgeries
VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial inThe Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomit...
2025-11-03 22:00
1025
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
* Spin-off finalized within five months following board resolution * Proposal approved in shareholders' meeting with 99.9% support * Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the ...
2025-11-03 20:00
1015
TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR Multicenter Randomized Controlled Trial
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly inSan Francisco ,USA, attracting widespread attention from the global cardiovascular community. On the morning ofOctober 28th (local time), during the "Innovation S...
2025-11-03 18:04
1255
Anthill Cloud: Transforming Pharma Marketing with AI, Modular Content, and Omnichannel Engagement
COPENHAGEN, Denmark, Nov. 3, 2025 /PRNewswire/ -- Anthill
2025-11-03 17:00
1074
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
* Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health c...
2025-11-03 16:48
1109
Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes. YOKOHAMA, Japan, Nov. 3, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment1, today announced th...
2025-11-03 14:35
1027
Sandstone Easydrip™ Plus with Hextra Tech™ Hexagonal Broad Hub Delivers Steadier, More Comfortable Insulin Injections
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- A peer-reviewed article by researchers at the University ofShanghai for Science and Technology (USST), published in an international biomedical engineering journal, reports that the Hextra Tech™ hexagonal, broad-platform hub used in Sandstone Easydrip™ Plus ...
2025-11-03 14:35
868
Biomom Reinvents "Snow" with Five-Layer Safety Packaging -- Stronger Protection and Greater Convenience for Kids' Probiotics
SEOUL, South Korea, Nov. 3, 2025 /PRNewswire/ -- Health supplement brand Biomom has introduced upgraded, hygienic packaging for its flagship probiotic "Biomom Snow." The renewal features five-layer safety stick and pillow packaging designed to enhance probiotic protection and ensure a more conve...
2025-11-03 14:00
765
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRA...
2025-11-03 13:26
906
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Desi...
2025-11-03 12:12
1031
MALAYSIA HEALTHCARE TRAVEL COUNCIL STRENGHTENS REGIONAL PRESENCE IN MEDAN THROUGH ASTINDO TRAVEL FAIR 2025
MEDAN, Indonesia, Nov. 3, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) continues to advance its regional outreach by participating in the ASTINDO Travel Fair (ATF) 2025, held inMedan, Indonesia. The event serves as one of the largest tourism exhibitions in the country, gathe...
2025-11-03 11:37
1004
OMANI PATIENTS GAIN DIRECT ACCESS TO MALAYSIAN MEDICAL SPECIALISTS THROUGH WEEK-LONG HEALTHCARE ACTIVATION
SEEB, Oman, Nov. 3, 2025 /PRNewswire/ -- Malaysia Healthcare Week opens at City Centre Mall, Seeb, marking the first majorMiddle East activation under the Malaysia Year of Medical Tourism (MYMT) 2026. The week-long programme connects Omani patients with Malaysian medical specialists through publi...
2025-11-03 11:19
1110
Oxford Instruments introduces the witec360 Raman Microscope with Hexalight Spectrometer to advance research in Singapore and across Southeast Asia
LONDON, Nov. 3, 2025 /PRNewswire/ -- Oxford Instruments today announced the launch of its witec360Raman microscope with the Hexalight spectrometer, setting a new benchmark in confocal Raman imaging and analysis. The new system delivers unprecedented optical performance, automation, and flexibilit...
2025-11-03 09:00
1068
Caregility and MOD3RN Care Partner to Modernise Healthcare Delivery in Australia
WALL, N.J. and BARANGAROO, Australia, Nov. 3, 2025 /PRNewswire/ -- Caregility Corporation, a global enterprise telehealth leader dedicated to connecting care for patients and clinicians everywhere through innovative virtual care and AI-powered solutions, today announced a strategic reseller partn...
2025-11-03 05:30
1110
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...
2025-10-31 21:00
2055
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 292 media titles]
2025-11-29 09:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 286 media titles]
2025-11-26 10:49
Lincah Acquires Orderfaz to Strengthen Southeast Asia's Social Commerce Infrastructure
[Picked up by 283 media titles]
2025-11-26 09:00
Singapore Hosts Record-Breaking World Robot Olympiad (WRO®) International Final 2025
[Picked up by 282 media titles]
2025-11-27 08:00
Most Read
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2500
